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In Balb/c (H-2d) mice, the nucleoprotein (NP) of measles virus (MV) induces a MHC class I restricted-CTL response to a
single 9-amino-acid epitope (aa 281–289). This Ld-restricted epitope is also present in the NP of the closely related canine
distemper virus (CDV). To investigate whether this epitope is immunologically effective when it is present within the primary
sequence of a nonviral protein, we have incorporated the 281–289 motif into the human CD36 protein. When cells are
infected with vaccinia virus (VV) recombinants expressing this protein, CD36NP, the MV epitope is correctly processed and
the cells are lysed by MVNP-specific CTLs. In vivo, VV-CD36NP induced CTLs which protected mice from a lethal dose of
CDV, but did not block virus replication. The MVNP contains four other potential Ld-restricted motifs. To investigate if these
could be utilized in the absence of the dominant epitope, a mutant NP was produced in which one of the anchor residues
in the aa 281–289 motif was mutated. Cells infected with a VV recombinant expressing this protein (VV-NP F289S) were
only poorly lysed by MVNP-specific CTLs. Similarly, immunization of Balb/c mice with VV-NP F289S induced a lower level
of CTL activity compared to the VV-NP, but the activity was now directed to three other epitopes. When mice were vaccinated
with VV-NP F289S they were only partially protected from a lethal CDV challenge. The significance of these results for MV
vaccine development is discussed. q 1996 Academic Press, Inc.
INTRODUCTION has failed to make a similar impact in the developing
countries. This is mainly due to the early age of measles
Vaccine strategies can attempt to block virus replica-
infection in these countries and the inefficacy of vaccina-
tion at two levels. The infectious agent may be neutral-
tion in the presence of maternal antibody.
ized by antibody before reaching the target cell or, if
To circumvent this problem, we have previously stud-the virus infection proceeds, the cytotoxic lymphocytes
ied the possibility of a vaccine based on vaccinia virus(CTLs) may eliminate the infected cells. Studies on the
(VV) recombinants expressing MV antigens (Drillien etevaluation of vaccines normally measure antibody levels,
al., 1988; Wild et al., 1992, 1993). We observed that de-as tests for cell-mediated responses are more compli-
spite an active replication of the VV–MV recombinants incated and costly on a routine basis. However, the ad-
the presence of passively administered anti-MV antibody,vances in cellular immunity of the past few years have
the humoral response to the MV antigens was inhibited.underlined the importance of this field in vaccine devel-
In contrast, however, the anti-MV CTL response was nor-opment. In principle, live attenuated virus vaccines in-
mal (Galletti et al., 1995). Although the immune statusduce the same immune responses as the wild-type virus
(protection) was not studied in this case, T cell immuniza-infections, i.e., both MHC class I and II cell-mediated
tion could be a strategy in order to ‘‘prime’’ individualsimmunity. In contrast, inactivated vaccines do not and,
for either vaccination with the attenuated virus or infec-in general, induce a class II response. Although a CTL
tions with the wild-type viruses.class I response has been attributed to be a major mech-
Our previous studies using Balb/c mice established thatanism in the recovery from disease for certain viruses,
the MV nucleoprotein (NP) induces a class I CTL responsethere remains a gap in our knowledge concerning the
which is Ld-restricted (Beauverger et al., 1993a). We showedrole of CTLs in protection and in pathogenesis.
that a 9-amino-acid peptide (aa 281–289) was the dominantA live attenuated measles virus (MV) vaccine has been
NP CTL epitope and that the corresponding synthetic pep-used for over 30 years. In the USA, endemic measles has
tide could sensitize target cells to lysis by MVNP-specificbeen virtually eliminated: the number of cases reported
CTLs. In the present study, we show that mutagenesis ofannually represents less than 1% of those before vaccina-
this epitope abrogates both its Ld-restricted presentationtion was initiated (Krugman, 1977). However, this vaccine
and its capacity to induce CTLs. The epitope could be in-
serted into a nonviral protein, human CD36, and as such1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (33) 72 72 25 67. was capable of inducing MVNP-specific CTLs in mice. Fur-
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FIG. 1. Structure of the human CD36 molecule (aa 319–335) encoding the MVNP CTL epitope and the MVNP protein mutated in one of the
anchor residues. The residues in bold are the residues that have been substituted.
thermore, when animals were challenged with a lethal dose Kk-NP) as described by Beauverger et al. (1993a,b, 1994).
of the closely related virus, canine distemper virus (CDV), P815 cells persistently infected with CDV were also used
which shares this CTL epitope, although they were not pro- (Beauverger et al., 1993a).
tected against infection they did not succumb to the disease. Mice and immunizations. Female BALB/c (H-2d) mice
were obtained from IFFA-CREDO, France. Five- to six-
MATERIALS AND METHODS week-old mice were immunized by tail scarification with
107 PFU of the VV recombinants in 10 ml of inoculum.Site-directed mutagenesis
One to three months later, the mice were boosted with
After insertion into the plasmid mp19 between the Hin- an intraperitoneal inoculation (ip) of 107 PFU and the CTL
dIII and XbaI sites, the cDNA encoding the human CD36 response was examined 1 month later.
protein (Oquendo et al., 1989) was mutated as previously Cytotoxic T-lymphocyte assays. Spleens were removed
described (Daviet et al., 1995) using the 5*-CTTCTTTGC- from immunized animals and, after elimination of red
ATTTGAATTCGTGTAGCCCAAGAGCTGGGTAACAAT blood cells by perfusion with DMEM, cocultivated with
TTTTTGAG-3* oligonucleotide. This oligonucleotide con- P815 or Ltk0 cells expressing the MV NP protein and
tains the NP 281–289 CTL epitope coding sequence, which had been incubated with mitomycin C (25 mg/ml)
flanked by sequences encoding respectively the aa 319– for 30 min at 377. The ratio of spleen to stimulator cells
322 and aa 332–335 regions of the CD36 protein. This was 10:1. The cocultures (11 1 106 cells/well) were dis-
oligonucleotide also contains an EcoRI site which was tributed in 24-well plates and incubated at 377 in DMEM–
inserted without affecting the amino acid sequence. This 10% FCS containing 5 1 1005 M 2-mercaptoethanol. On
site was used to select the mutated version of mp19- Day 5, half the medium was changed and the cytotoxic
CD36 (mp19-CD36-NP281 – 289). activity tested on Day 7.
The NP gene of MV strain (Buckland et al., 1988), once
For the CTL assays P815, P815 Kk, P815-NP, or P815
inserted into the mp19 plasmid between the SalI and
Kk-NP cells were radiolabeled with 50 mCi 51Cr for 90
EcoRI sites, was mutated by a similar procedure using
min at 377, washed twice in DMEM–1% FCS, and incu-the 5*-CTCACCATCAGATTCATGCAGGCCTAGAGCAG-
bated for 1 hr in DMEM–10% FCS before a last wash.GATAC-3* oligonucleotide. This oligonucleotide codes
In some experiments, cells were infected overnight withfor the aa 281–292 region of the NP protein but contains
vaccinia recombinants before radiolabeling. Experimentsa serine residue at position 289 instead of a phenylala-
using synthetic peptides (2 1 1007 M) were performednine. A positive clone (mp19-NPF289S) was selected by
as previously described (Beauverger et al., 1993a). Thevirtue of the StuI site present in the above-mentioned
assays and expression of results were as previously de-oligonucleotide.
scribed (Beauverger et al., 1993a).
Construction of vaccinia virus recombinants
VV recombinants were prepared using the host-range Mouse protection studies
selection system as described by Perkus et al. (1989).
Briefly, the genes to be expressed were subcloned into Five-week-old Balb/c mice were immunized twice ip
the pCOPAK H6 plasmid (Perkus et al., 1989), which also with 107 PFU of the VV recombinants with a 2-week inter-
contains the KIL vaccinia gene. Vero cells were infected val. Two weeks after the second immunization, the mice
with the NYVAC strain of VV (Tartaglia et al., 1992) and were challenged by intracerebral (ic) inoculation with 4
transfected with the pCOPAK plasmid. The VV recombi- 1 102 PFU/mouse of a neuroadapted strain of CDV (Ber-
nants were selected on RK13 cells. nard et al., 1983). The mice were observed for 6 months
after the challenge. Deaths only occurred in the initial
Cells, immunization, and CTL assays acute phase of the disease. Sera were taken by retro-
orbital bleeding 2 months after the challenge and theCells. The cell line used as target cells in CTL assays
CDV-neutralizing antibody titers were determined in Verowas P815 (H-2d) and P815 Kk and derivatives of these
cells expressing high levels of MVNP (P815-NP and P815 cells as previously described (Wild and Huppert, 1980).
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FIG. 2. Antigen presentation of the MVNP epitope by VV-CD36NP. P815 cells were infected with VV-CD36NP and tested for lysis with MVNP-
specific CTLs. P815-NP cells were used as a positive control.
RESULTS combinant. The spleen-derived cells were stimulated in
vitro with P815-NP cells and then tested in a lysis assay
Construction of a VV recombinant expressing a single against P815-NP or CDV-infected P815 cells. The CTLs
MV CTL epitope induced by VV-CD36NP specifically lysed both types of
cells (Fig. 3), confirming that the epitope 281–289 isOur previous observations showed that when Balb/c
equally active in both viral systems and that the epitopemice are immunized with VV-MVNP they are partially
within the CD36 protein was presented and inducedprotected against an ic challenge with CDV (Wild et al.,
CTLs in Balb/c mice.1993). The MVNP encodes a single Ld-restricted CTL
epitope which is identical in the CDVNP (aa 281–289)
(Beauverger et al., 1993a). In order to determine if this Protection against CDV after VV-CD36 NP
single epitope was responsible for the protection, we immunization
constructed a VV recombinant in which the epitope was
To study the protection afforded by the epitope 281–expressed from within the human CD36 molecule (Fig.
289, Balb/c mice were immunized twice, 2 weeks apart,1). Infection of murine (P815) cells with this recombinant,
with the VV-CD36NP recombinant and challenged 2VV-CD36NP, and immunofluorescent studies using anti-
weeks after the second immunization by ic inoculationCD36 monoclonal antibodies established that the ex-
of a neuroadapted CDV strain (Fig. 4). Whereas in thepression and distribution of the CD36 protein was not
control group vaccinated with VV-CD36 only 20% sur-modified by the insertion of the MV epitope (not shown).
vived, mice vaccinated with VV-CD36NP had a 79% sur-
vival rate.Processing, presentation, and induction of CTLs by
Despite this high level of protection with the latterVV-CD36NP
recombinant, most of the animals initially became mori-
To study if the MVNP epitope could be processed and bund before recovering. Analysis of the sera from these
presented from within the context of the CD36 molecule, animals taken 2 months after the challenge showed that
P815 cells were infected with the VV-CD36NP recombi- all had CDV-neutralizing antibodies, indicating that the
nant and their sensitivity to lysis by MVNP CTLs was challenge virus had replicated to give a substantial anti-
studied. The latter were from VV-NP-immunized mice genic challenge (Table 1).
which had been restimulated with P815-NP cells. The
cells were lysed to the same level as P815 cells Recognition of minor MVNP CTL epitopes
transfected with the MVNP gene, confirming that the epi-
tope is processed and presented (Fig. 2). In our previous studies, we observed that in Balb/c
mice immunized with VV-NP the major response was toBalb/c mice were immunized with the VV-CD36NP re-
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FIG. 3. Induction of MV CTLs in mice by VV-CD36NP. Balb/c mice were immunized with (a) VV-CD36NP or (b) VV-CD36. One month later their
spleen cells were stimulated with P815-NP cells and then tested for their capacity to lyse P815-NP and CDV-infected cells.
epitope 281–289. However, four other potential Ld-motifs, lysed compared to the positive controls (P815-NP), con-
firming that the majority of the CTL activity was directedi.e., proline at position 2 and a hydrophobic amino acid
at position 9 (Corr et al., 1992), were present. To evaluate against epitope 281–289. The residual activity against
VV-NP F289S could be due either to reduced activity ofif these alternative motifs could be used in the absence
of the dominant epitope, we mutated one of the anchor the mutated sequence or to the presentation of peptides
representing the other motifs.residues in the epitope (289 phenylalanine to serine).
This modified NP gene (NP F289S) was expressed from
a VV recombinant and shown to have similar properties Induction of minor CTL epitope responses with VV-
(immunofluorescence, cell distribution, etc.) to the un- NP F289S
modified version of NP (data not shown).
To study if the MVNP-induced CTL population could To investigate if the other Ld-motifs present in the
MVNP could induce CTLs in the absence of the majorrecognize the NP F289S version, CTLs induced by VV-
NP were tested in a lysis assay using P815 target cells epitope (281–289), Balb/c mice were immunized with VV-
NP F289S and tested for CTL activity using peptidesinfected with VV-NP F289S (Fig. 5). The latter were poorly
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FIG. 4. Protection of Balb/c mice after vaccination with VV-CD36NP.
Mice were immunized twice with the VV recombinants and challenged
2 weeks after the second immunization by ic inoculation of CDV. FIG. 5. Antigen presentation by the mutated MVNP F289S. P815 cells
were infected with VV-NP F289S and analyzed for lysis using MVNP
CTLs. P815-NP cells were used as the positive control.
representing the predicted motifs. As shown in Fig. 6,
the original major NP 281 –289 epitope (P4) is no longer
reduced CTL response of VV-NP F289S induced in Balb/recognized, whereas P815 cells incubated with peptides
c mice is not due to a problem of processing and presen-corresponding to amino acids 243–251, 329–337, and
tation of the NP F289S protein, but is due to the absence411–419 sensitized the cells for lysis. There was no re-
of the dominant NP 281–289 CTL epitope.sponse to these peptides when the mice were immu-
nized with VV-NP. This shows that in the absence of the
Protection of mice against CDV infection by VV-NPmajor CTL epitope, minor epitopes can induce CTLs.
F289SThe lower level of CTL activity induced by VV-NP
F289S compared with the unmutated protein may be due In order to evaluate the protective effect of the NP in
to changes in protein structure of the mutated protein the absence of the major CTL epitope, Balb/c mice were
affecting its recognition by CTLs. In our previous studies
we showed that MVNP induces a strong Kk-restricted
CTL response in C3H mice (Beauverger et al., 1994).
Thus, to exclude the problem of epitope presentation by
the NP F289S protein, we immunized C3H mice with VV-
NP F289S and studied the Kk-restricted CTL response
(Fig. 7). The results show that the CTLs derived from VV-
NP F289S efficiently recognize P815 Kk-NP and P815 Kk
CDV-infected cells, thus clearly demonstrating that the
TABLE 1
Serum Antibody (CDV) Neutralization Titers of Mice Vaccinated
with VV-CD36NP and Challenged with CDV
Mouse Prechallenge Postchallenge
1 20 160
2 20 320
3 20 40
4 20 20
5 20 80
6 20 80 FIG. 6. Induction and specificity of a CTL response in Balb/c mice
by VV-NP F289S. Mice were immunized with VV-NP F289S. One month
later the spleen cells were stimulated with P815-NP cells and thenNote. Balb/c mice were vaccinated twice at 2-week intervals with
VV-CD36NP and then challenged 2 weeks later with CDV. Sera taken tested for lysis with P815 cells incubated with the different NP peptides:
P1 aa 61–69, P2 83–91, P3 243–251, P4 281–289, P5 329–337, andprior to the challenge and 2 months after were tested for CDV-neutraliz-
ing antibody. P6 411–419.
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immunized twice with VV-NP F289S with a 2-week inter-
val and then challenged 2 weeks later by ic inoculation
with CDV. As shown in Fig. 8, only 40% of the mice
were protected compared to 90% immunized with the
unmutated NP.
DISCUSSION
The type of immune response required for protection
against viral diseases probably depends on the nature of
the infection. In general, high levels of virus-neutralizing
serum antibodies protect, and CTLs play a secondary
role in clearing an infection. Furthermore, it has been
shown that certain viral infections rely more on one arm
of the immune system than the other. However, there are
a number of examples, especially in HIV infections, in
which despite high levels of HIV-specific CTLs the infec- FIG. 8. Protection of Balb/c mice after immunization with VV-NP
F289S. Mice were vaccinated twice with the VV recombinants (VV-NP,tion is not controlled. A number of mechanisms have
VV-NP F289S, or VV-CD36) and challenged 2 weeks after the secondbeen shown to be operative under these circumstances,
immunization by ic inoculation of CDV.including the generation of escape mutants and antago-
nistic epitopes (Bertoletti et al., 1994; Klenerman et al.,
1994). Thus a better understanding of CTL use and pre-
mia, which is not surprising if the function of CTLs is to
sentation is necessary for the future design of vaccines.
clear infected cells.
In our previous studies, we observed that mice immu-
In similar experiments with cytomegalovirus, Del Val
nized with the VV-MVNP recombinant were partially pro-
et al. (1991) protected animals with an epitope from an
tected from a fatal challenge with the closely related
immediate-early protein. However, Eisenlohr et al. (1992)
CDV. In this study, we have been able to reproduce these
showed that the flanking sequences of the epitope can
results by transferring a single Ld-restricted class I epi-
play a regulatory role in the epitope presentation. We
tope (aa 281–289) into a protein of nonviral origin (human
initially identified the CTL epitopes using predicative mo-
CD36). In this new context, the epitope was correctly
tifs (Corr et al., 1992). In mice immunized with VV-NP,
processed and induced MVNP-specific CTLs. Further-
of the five potential Ld-epitopes, aa 281–289 was the
more, mice were protected against a fatal challenge.
dominant epitope. This was further confirmed by intro-
However, the animals were not protected against a vire-
ducing a mutation in one of the anchor residues. If similar
mutations should arise in nature then CTLs may be in-
duced by another viral protein or the other potential epi-
topes may be favored. In lymphochoriomengitis virus in-
fections of H-2b mice, there are three major CTL epitopes,
two on the glycoprotein and one on the nucleoprotein.
Mutation in all three epitopes led to the generation of a
novel CTL response to the viral L protein (Lewicki et al.,
1995). Although this response was comparatively
weaker, it was protective. In the present study, we asked
the question if the dominant epitope was mutated, would
the minor epitopes be functionally active. We found that
the minor epitopes could be presented and induce CTLs,
although the protection in this case was not as efficient
as that observed with the unmodified protein.
The results presented show that protection from a le-
thal infection can be obtained with a single CTL epitope,
but this does not block virus infection. In the evaluation
of vaccines, the inhibition of clinical symptoms and virus
replication are studied in animal models. In the case of
the MV CTL epitopes, the criteria would not be met, yet
FIG. 7. VV-NP F289S induces a normal H-2k CTL response. C3H mice in the model system presented, there was obviously anwere immunized with VV-NP F289S. One month later the spleen cells
advantage in vaccinating for a CTL response. We nowwere stimulated with L-NP (H-2k) cells and their CTL activity was tested
on P815 Kk-NP and P815 Kk-CDV infected cells. need to examine in more relevant models if a primary
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CD36 antigen using human–mouse chimaeric proteins and homo-CTL response helps in the recovery from MV infection.
logue-replacement mutagenesis. Biochem. J. 305, 221–224.Such an approach may eventually be considered for the
Del Val, M., Schlicht, H., Volkmer, H., Messerle, M., Reddehase, M.,
vaccination of young children whose level of maternal and Koszinowski, U. (1991). Protection against lethal cytomegalovirus
antibody would block conventional measles vaccines. infection by a recombinant vaccine containing a single nonameric
T-cell epitope. J. Virol. 65, 3641–3646.
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